Clinical Trial

Pharmacokinetic Study of Buagafuran Capsules in Participants With Hepatic Impairment and Normal Hepatic Function

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study adopts a non-randomized, open label, parallel, single-dose design to evaluate the safety and pharmacokinetic characteristics of Buagafuran capsules in participants with hepatic impairment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-03.
Trial Details
NCT Number NCT07457190
Lead Sponsor Beijing Union Pharmaceutical Factory Ltd
Conditions Generalized Anxiety Disorder
Enrollment 24 participants
Start Date 2026-03
Primary Completion 2026-08 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-10